<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884880</url>
  </required_header>
  <id_info>
    <org_study_id>2020006P4A01</org_study_id>
    <nct_id>NCT04884880</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Luo-Fu-Shan Plaster in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled Clinical Trial of Luo-Fu-Shan Plaster in the Treatment of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy and safety of Luo-Fu-Shan Plaster in patients&#xD;
      with Rheumatoid Arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are inspired by Chinese traditonal herb, an therapy for thousands of years,&#xD;
      and take its advantage to make Luo-Fu-Shan Plaster in order to get an effective and safe&#xD;
      treatment for active RA patients. The study is a multicenter, randomized, double-blind,&#xD;
      placebo-controlled trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 14, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>180 subjects will be randomized to two parallel groups (90 subjects per group) to receive Luo-Fu-Shan Plaster 10g once daily. Placebo will be administered to individuals randomized to that treatment group in a form identical to the Luo-Fu-Shan Plaster. The first investigational medicinal product dose will be administered the day after the randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of Visual Analogue Scale(VAS) pain score</measure>
    <time_frame>Day 1 to Week 4</time_frame>
    <description>The changes of Visual Analogue Scale(VAS) pain score of global health status, the patient's assessment of pain on a visual analogue scale.&#xD;
The score their pain intensity in the most affected joint on a 0-10 cm Visual Analogue Scale Score (VAS), ranging from no pain (0) to extremely pain (10).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of the Disease Activiyu Score (DAS28)</measure>
    <time_frame>Day 1 to Week 4</time_frame>
    <description>The changes of the Disease Activity Score (DAS28).The score their pain intensity in the most affected joint on a 0-10 cm Disease Activity Score (DAS28), ranging from no pain (0) to extremely pain (10).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The score of the Health Assessment Questionnaire (HAQ-DI)</measure>
    <time_frame>Day1 to Week 4</time_frame>
    <description>the patient's assessment of function using a modified version of the Health Assessment Questionnaire (HAQ).The score their level, ranging from no difficuties(0),some difficulties(1),a lot of difficuties(2) to coud not finish(3).</description>
  </other_outcome>
  <other_outcome>
    <measure>The score of the RA-PRO</measure>
    <time_frame>Day 1 to Week 4</time_frame>
    <description>the patient's assessment of function using a modified version of the RA-PRO which ranging from 0 to 3.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Luo-Fu-Shan Plaster 10g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10g，once daily，4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10g，once daily，4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luo-Fu-Shan Plaster</intervention_name>
    <description>Luo-Fu-Shan Plaster 10g，once daily，4 weeks</description>
    <arm_group_label>Luo-Fu-Shan Plaster 10g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The placebo 10g</intervention_name>
    <description>Placebo 10g，once daily，4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects aged 18 to 75 years (time of get informed consent)&#xD;
&#xD;
          -  Documented diagnosis of rheumatoid arthritis, as defined by the American Rheumatism&#xD;
             Association 1987 Revised Criteria.&#xD;
&#xD;
          -  Documented diagnosis of damp-heat syndrome according to Traditional Chinese Medicine.&#xD;
&#xD;
          -  If patients are receiving Disease-modifying anti-rheumatic drugs (DMARDs), then the&#xD;
             doses should have been kept stable for at least 12 weeks.&#xD;
&#xD;
          -  If patients are receiving non-steroidal anti-inflammatory drugs (NSAIDs) or orally&#xD;
             Chinese herbal medicine, then the doses should have been kept stable for at least 4&#xD;
             weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Skin allergies or broken skin;&#xD;
&#xD;
          -  Taking glucocorticoids,more than 10 mg daily.&#xD;
&#xD;
          -  Female patients who are pregnant, breast-feeding or planed to be pregnant;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Quan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guang'anmen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Quan, PhD</last_name>
    <phone>86-010-88001132</phone>
    <email>doctorjq@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Quan Jiang</investigator_full_name>
    <investigator_title>Director,Devision of Rhenumatology</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>External therapy</keyword>
  <keyword>Herb medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

